Perspectives on Cancer Genome Profiling

PGDx BLOG

PGDx Takes on ASCO

Every year, 40,000 oncology professionals gather in Chicago for ASCO (American Society of Clinical Oncology), the largest cancer conference in the world. Presenters at this meeting reveal new findings on promising therapies, introduce intriguing theories on anything from cancer biology to clinical practice, and inevitably spark controversial discussions from around the field…

MSI 2.0

On May 23, the FDA announced it has granted accelerated approval of Merck’s PD-1 inhibitor Keytruda (pembrolizumab) for use as a pan-cancer therapeutic in solid tumors with detectable levels of the microsatellite instability-high (MSI-H) biomarker. This is the first time the FDA has approved a cancer treatment targeting a specific genetic feature…

Genomic Predictors of Immunotherapy Response

One of the most cutting-edge pan-cancer biomarkers for response to cancer therapeutics is microsatellite instability (MSI). Resulting from deficient mismatch-repair (MMR), MSI is a clinically relevant condition characterized by the progressive shortening of mononucleotide genomic tracts. With recent advances in precision medicine, our ability to detect MMR deficiency in patients has taken…

Tumor Evolution: A Resistance Mechanism To Checkpoint Blockade Inhibitors

Tumor cells are readily targeted and destroyed by the body’s army of cytotoxic T cells.  Normally, checkpoint blockade proteins on the outer membrane of T cells, such as programmed death 1 (PD-1) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), distinguish between “self” and “non-self” cells. Checkpoint blockade inhibitors (CBIs), such as anti-PD-L1 (pembrolizumab)…